Comparing TAK-928 to docetaxel for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic squamous non-small cell lung cancer that cannot be removed by surgery.
- Your cancer has grown after or during treatment with both a checkpoint inhibitor (like Keytruda or Opdivo) and a platinum-based chemotherapy (like carboplatin and paclitaxel).
- You have not had a docetaxel treatment before, and you do not have certain genetic changes in your tumor (like EGFR or ALK).
- If you have had brain metastases, they must be stable and not causing symptoms for at least 4 weeks.
- You are generally in good health (able to take care of yourself), and your kidney, liver, and blood counts are within a certain range.
- You must be willing to provide a tumor tissue sample (fresh biopsy or stored from the last 2 years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
This study tests a new drug (7MW3711) against a standard chemotherapy (docetaxel) for people with advanced squamous non-small cell lung cancer that has progressed after prior chemo-immunotherapy. The goal is to see if the new drug is more effective or has fewer side effects.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new drug called datopotamab deruxtecan against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has already been treated. The new drug targets a protein called TROP2 found on cancer cells, which may help slow or stop the cancer's growth.
This trial tests a new drug combination for a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the combination can help people whose cancer has grown after standard treatments.
This study tests a new drug called JSKN016 in people with advanced non-small cell lung cancer whose standard treatments have stopped working. The drug may help shrink tumors or slow the cancer's growth, and the study looks at safety and effectiveness.
Hear when a new IO-resistant sqNSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.